ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO406

Implementing Comprehensive Genetic Testing in Patients with Kidney Disease Improves Care by Identifying the Basis for a Wide Variety of Renal Phenotypes

Session Information

Category: Genetic Diseases of the Kidneys

  • 1002 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • Thomas, Christie P., University of Iowa, Iowa City, Iowa, United States
  • Mansilla, M. Adela, University of Iowa, Iowa City, Iowa, United States
  • Freese, Margaret E., University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
  • Kimble, Mycah J., University of Iowa, Iowa City, Iowa, United States
  • Campbell, Colleen Ann, University of Iowa, Iowa City, Iowa, United States
  • Smith, Richard J., University of Iowa, Iowa City, Iowa, United States
Background

The clinical diagnosis of genetic renal diseases may be limited by the overlapping spectrum of manifestations between diseases or by the advancement of disease where clues to the original process is absent. The objective of this study was to determine whether genetic testing informs diagnosis and facilitates management of kidney disease patients.

Methods

We developed a comprehensive genetic testing panel (KidneySeq) to evaluate patients with various phenotypes including cystic diseases, congenital anomalies of the kidney and urinary tract (CAKUT), tubulointerstitial diseases, transport disorders and glomerular diseases. We evaluated this panel in 127 consecutive patients ranging in age from newborns to 81 years who had samples sent in for genetic testing.

Results

The performance of the sequencing pipeline for single nucleotide variants was validated using CEPH controls and for indels using Genome-in-a-Bottle. To test the reliability of the copy number variant analysis, positive samples were re-sequenced and analyzed. For patient samples, a multidisciplinary review board interpreted genetic results in the context of clinical data. A genetic diagnosis was made in 56 (44%) patients and ranged from 56% for ciliopathies/tubulointerstitial diseases, 46% for CAKUT, 45% for transport disorders and 35% for glomerulopathies. Pathogenic and likely pathogenic variants included 46% missense, 13% nonsense, 5% splice site variants, 22% insertion-deletions and 13% copy number variants. In 15 cases, the genetic result changed the clinical diagnosis.

Conclusion

Comprehensive genetic testing should be considered in the evaluation of renal patients as it complements other tests and provides insight into the underlying disease and its management.

Outcome of comprehensive gene panel testing in 127 renal patients